FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3113077828> ?p ?o ?g. }

• W3113077828 endingPage "e134" @default.
• W3113077828 startingPage "e122" @default.
• W3113077828 abstract "Background Poly(ADP-ribose) polymerase (PARP) inhibitors have shown efficacy and acceptable safety in a range of neoplasms, particularly in ovarian cancers. However, some concerns have emerged regarding rare and delayed adverse events including cases of myelodysplastic syndrome and acute myeloid leukaemia, for which data are scarce. The aim of this study was to estimate the risk of myelodysplastic syndrome and acute myeloid leukaemia related to PARP inhibitors, via a systematic review and safety meta-analysis, and to describe clinical features of PARP inhibitor-related myelodysplastic syndrome and acute myeloid leukaemia cases reported in WHO's pharmacovigilance database (VigiBase). Methods We systematically reviewed randomised controlled trials (RCTs) comparing PARP inhibitor therapy versus control treatments (placebo and non-placebo) in adults (age ≥18 years) treated for cancer in MEDLINE, the Cochrane Central Register of Controlled Trials, and the ClinicalTrials.gov registry with ongoing surveillance up to May 31, 2020. The date range for included studies was not restricted. By a stepwise method to capture all available adverse events, we first extracted data on myelodysplastic syndrome and acute myeloid leukaemia cases from ClinicalTrials.gov. If cases were not available, we extracted them from published manuscripts, or subsequently contacted corresponding authors or sponsors to provide data. RCTs without available data from ClinicalTrials.gov, publications, or corresponding authors or sponsors were excluded. The primary outcome was the summary risk of myelodysplastic syndrome and acute myeloid leukaemia related to PARP inhibition versus placebo treatment in RCTs. We used a fixed-effects meta-analysis to obtain Peto odds ratios (ORs) with 95% CIs. In a separate observational, retrospective, cross-sectional pharmacovigilance study of VigiBase, cases of myelodysplastic syndrome and acute myeloid leukaemia related to PARP inhibitor therapy were extracted on May 3, 2020, and clinical features summarised with a focus on median duration of PARP inhibitor exposure, median latency period between first drug exposure and diagnosis, and proportion of cases resulting in death. Our systematic review and safety meta-analysis were registered with PROSPERO, CRD42020175050. Our retrospective pharmacovigilance study was registered on ClinicalTrials.gov, NCT04326023. Findings For our safety meta-analysis, initial searches identified 1617 citations, and 31 RCTs were systematically reviewed for eligibility. 28 RCTs with available adverse events were analysed (18 placebo and ten non-placebo RCTs), with 5693 patients in PARP inhibitor groups and 3406 patients in control groups. Based on the 18 placebo RCTs (n=7307 patients), PARP inhibitors significantly increased the risk of myelodysplastic syndrome and acute myeloid leukaemia compared with placebo treatment (Peto OR 2·63 [95% CI 1·13–6·14], p=0·026) with no between-study heterogeneity (I2=0%, χ2 p=0·91). The incidence of myelodysplastic syndrome and acute myeloid leukaemia across PARP inhibitor groups was 0·73% (95% CI 0·50–1·07; I2=0%, χ2 p=0·87; 21 events out of 4533 patients) and across placebo groups was 0·47% (0·26–0·85; I2=0%, χ2 p=1·00; three events out of 2774 patients). All 28 RCTs were rated as having unclear risk of bias. In VigiBase, 178 cases of myelodysplastic syndrome (n=99) and acute myeloid leukaemia (n=79) related to PARP inhibitor therapy were extracted. In cases with available data, median treatment duration was 9·8 months (IQR 3·6–17·4; n=96) and median latency period since first exposure to a PARP inhibitor was 17·8 months (8·4–29·2; n=58). Of 104 cases that reported outcomes, 47 (45%) resulted in death. Interpretation PARP inhibitors increased the risk of myelodysplastic syndrome and acute myeloid leukaemia versus placebo treatment. These delayed and often lethal adverse events should be studied further to improve clinical understanding, particularly in the front-line maintenance setting. Funding None. Poly(ADP-ribose) polymerase (PARP) inhibitors have shown efficacy and acceptable safety in a range of neoplasms, particularly in ovarian cancers. However, some concerns have emerged regarding rare and delayed adverse events including cases of myelodysplastic syndrome and acute myeloid leukaemia, for which data are scarce. The aim of this study was to estimate the risk of myelodysplastic syndrome and acute myeloid leukaemia related to PARP inhibitors, via a systematic review and safety meta-analysis, and to describe clinical features of PARP inhibitor-related myelodysplastic syndrome and acute myeloid leukaemia cases reported in WHO's pharmacovigilance database (VigiBase). We systematically reviewed randomised controlled trials (RCTs) comparing PARP inhibitor therapy versus control treatments (placebo and non-placebo) in adults (age ≥18 years) treated for cancer in MEDLINE, the Cochrane Central Register of Controlled Trials, and the ClinicalTrials.gov registry with ongoing surveillance up to May 31, 2020. The date range for included studies was not restricted. By a stepwise method to capture all available adverse events, we first extracted data on myelodysplastic syndrome and acute myeloid leukaemia cases from ClinicalTrials.gov. If cases were not available, we extracted them from published manuscripts, or subsequently contacted corresponding authors or sponsors to provide data. RCTs without available data from ClinicalTrials.gov, publications, or corresponding authors or sponsors were excluded. The primary outcome was the summary risk of myelodysplastic syndrome and acute myeloid leukaemia related to PARP inhibition versus placebo treatment in RCTs. We used a fixed-effects meta-analysis to obtain Peto odds ratios (ORs) with 95% CIs. In a separate observational, retrospective, cross-sectional pharmacovigilance study of VigiBase, cases of myelodysplastic syndrome and acute myeloid leukaemia related to PARP inhibitor therapy were extracted on May 3, 2020, and clinical features summarised with a focus on median duration of PARP inhibitor exposure, median latency period between first drug exposure and diagnosis, and proportion of cases resulting in death. Our systematic review and safety meta-analysis were registered with PROSPERO, CRD42020175050. Our retrospective pharmacovigilance study was registered on ClinicalTrials.gov, NCT04326023. For our safety meta-analysis, initial searches identified 1617 citations, and 31 RCTs were systematically reviewed for eligibility. 28 RCTs with available adverse events were analysed (18 placebo and ten non-placebo RCTs), with 5693 patients in PARP inhibitor groups and 3406 patients in control groups. Based on the 18 placebo RCTs (n=7307 patients), PARP inhibitors significantly increased the risk of myelodysplastic syndrome and acute myeloid leukaemia compared with placebo treatment (Peto OR 2·63 [95% CI 1·13–6·14], p=0·026) with no between-study heterogeneity (I2=0%, χ2 p=0·91). The incidence of myelodysplastic syndrome and acute myeloid leukaemia across PARP inhibitor groups was 0·73% (95% CI 0·50–1·07; I2=0%, χ2 p=0·87; 21 events out of 4533 patients) and across placebo groups was 0·47% (0·26–0·85; I2=0%, χ2 p=1·00; three events out of 2774 patients). All 28 RCTs were rated as having unclear risk of bias. In VigiBase, 178 cases of myelodysplastic syndrome (n=99) and acute myeloid leukaemia (n=79) related to PARP inhibitor therapy were extracted. In cases with available data, median treatment duration was 9·8 months (IQR 3·6–17·4; n=96) and median latency period since first exposure to a PARP inhibitor was 17·8 months (8·4–29·2; n=58). Of 104 cases that reported outcomes, 47 (45%) resulted in death. PARP inhibitors increased the risk of myelodysplastic syndrome and acute myeloid leukaemia versus placebo treatment. These delayed and often lethal adverse events should be studied further to improve clinical understanding, particularly in the front-line maintenance setting." @default.
• W3113077828 created "2020-12-21" @default.
• W3113077828 creator A5001069481 @default.
• W3113077828 creator A5007606531 @default.
• W3113077828 creator A5033805399 @default.
• W3113077828 creator A5057002841 @default.
• W3113077828 creator A5058425515 @default.
• W3113077828 creator A5067055109 @default.
• W3113077828 creator A5073713547 @default.
• W3113077828 creator A5076438320 @default.
• W3113077828 creator A5079842256 @default.
• W3113077828 creator A5082323092 @default.
• W3113077828 date "2021-02-01" @default.
• W3113077828 modified "2023-10-06" @default.
• W3113077828 title "Myelodysplastic syndrome and acute myeloid leukaemia in patients treated with PARP inhibitors: a safety meta-analysis of randomised controlled trials and a retrospective study of the WHO pharmacovigilance database" @default.
• W3113077828 cites W1882891727 @default.
• W3113077828 cites W1989991921 @default.
• W3113077828 cites W2033816200 @default.
• W3113077828 cites W2043658255 @default.
• W3113077828 cites W2147071985 @default.
• W3113077828 cites W2150878386 @default.
• W3113077828 cites W2160466424 @default.
• W3113077828 cites W2194177867 @default.
• W3113077828 cites W2255822460 @default.
• W3113077828 cites W2263572070 @default.
• W3113077828 cites W2309983655 @default.
• W3113077828 cites W2523463218 @default.
• W3113077828 cites W2528228811 @default.
• W3113077828 cites W2531125083 @default.
• W3113077828 cites W2611183622 @default.
• W3113077828 cites W2621271973 @default.
• W3113077828 cites W2737389832 @default.
• W3113077828 cites W2749642104 @default.
• W3113077828 cites W2754327139 @default.
• W3113077828 cites W2763602017 @default.
• W3113077828 cites W2767110284 @default.
• W3113077828 cites W2779062531 @default.
• W3113077828 cites W2788106879 @default.
• W3113077828 cites W2793269924 @default.
• W3113077828 cites W2806421431 @default.
• W3113077828 cites W2808238124 @default.
• W3113077828 cites W2886477543 @default.
• W3113077828 cites W2887033855 @default.
• W3113077828 cites W2890799019 @default.
• W3113077828 cites W2893157368 @default.
• W3113077828 cites W2896628407 @default.
• W3113077828 cites W2897430921 @default.
• W3113077828 cites W2903466791 @default.
• W3113077828 cites W2906323921 @default.
• W3113077828 cites W2906986535 @default.
• W3113077828 cites W2947826965 @default.
• W3113077828 cites W2951058429 @default.
• W3113077828 cites W2975141952 @default.
• W3113077828 cites W2976139792 @default.
• W3113077828 cites W2980121911 @default.
• W3113077828 cites W2994977341 @default.
• W3113077828 cites W2995342757 @default.
• W3113077828 cites W3001713806 @default.
• W3113077828 cites W3006801800 @default.
• W3113077828 cites W3020771563 @default.
• W3113077828 cites W3028739923 @default.
• W3113077828 doi "https://doi.org/10.1016/s2352-3026(20)30360-4" @default.
• W3113077828 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33347814" @default.
• W3113077828 hasPublicationYear "2021" @default.
• W3113077828 type Work @default.
• W3113077828 sameAs 3113077828 @default.
• W3113077828 citedByCount "122" @default.
• W3113077828 countsByYear W31130778282021 @default.
• W3113077828 countsByYear W31130778282022 @default.
• W3113077828 countsByYear W31130778282023 @default.
• W3113077828 crossrefType "journal-article" @default.
• W3113077828 hasAuthorship W3113077828A5001069481 @default.
• W3113077828 hasAuthorship W3113077828A5007606531 @default.
• W3113077828 hasAuthorship W3113077828A5033805399 @default.
• W3113077828 hasAuthorship W3113077828A5057002841 @default.
• W3113077828 hasAuthorship W3113077828A5058425515 @default.
• W3113077828 hasAuthorship W3113077828A5067055109 @default.
• W3113077828 hasAuthorship W3113077828A5073713547 @default.
• W3113077828 hasAuthorship W3113077828A5076438320 @default.
• W3113077828 hasAuthorship W3113077828A5079842256 @default.
• W3113077828 hasAuthorship W3113077828A5082323092 @default.
• W3113077828 hasConcept C126322002 @default.
• W3113077828 hasConcept C143998085 @default.
• W3113077828 hasConcept C187212893 @default.
• W3113077828 hasConcept C197934379 @default.
• W3113077828 hasConcept C2780007613 @default.
• W3113077828 hasConcept C2780817109 @default.
• W3113077828 hasConcept C2993296363 @default.
• W3113077828 hasConcept C41008148 @default.
• W3113077828 hasConcept C535046627 @default.
• W3113077828 hasConcept C57658597 @default.
• W3113077828 hasConcept C71924100 @default.
• W3113077828 hasConcept C77088390 @default.
• W3113077828 hasConcept C95190672 @default.
• W3113077828 hasConceptScore W3113077828C126322002 @default.
• W3113077828 hasConceptScore W3113077828C143998085 @default.
• W3113077828 hasConceptScore W3113077828C187212893 @default.
• W3113077828 hasConceptScore W3113077828C197934379 @default.

• next